MétaCan
Menu
Back to cohort

P.180: Results of CDC-XM and FCXM cross-match in highly sensitized patients with CKD.

2024· article· en· W4402798718 on OpenAlexaboutno aff
Aida Turganbekova, Didara Khamitova, Mels Asykbaev, Zhamilya Saparbay, Sait Abdugaparov, Zhulduz Zhanzakova, Saniya Abdrakhmanova

Bibliographic record

VenueTransplantation · 2024
Typearticle
Languageen
FieldMedicine
TopicTraditional Chinese Medicine Studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineInternal medicine

Abstract

fetched live from OpenAlex

A compatibility test is a necessary test that is performed before kidney transplantation to confirm the compatibility of the donor and recipient to prevent acute antibody-mediated rejection. CDC-XM may be false-positive in recipients with an autoimmune disease or in patients who have previously been treated with desensitization protocols such as rituximab, antithymocyte globulin, or intravenous immunoglobulins. Our aim was to examine the outcome of FCXM in highly sensitized CKD patients with positive CDC-XM. 5 patients with a high percentage of antibodies were studied and one patient with a negative HLA antibody status was taken as a control and received desensitizing therapy with a single administration of rituximab at a dose of 375 mg per body area. Antibodies were determined using Luminex technology (Luminex Corp., USA) and the SAB (single antigen bead) method (OneLambda, USA). SAB analysis, CDC-XM and FCXM were performed before and after rituximab therapy. For XM analyses, lymphocytes were isolated on a density gradient using negative selection cell isolation technology using RosetteSep kits (StemCell technologies, Canada). FCXM was supplied with FlowDSA-XM™ reagents (OneLambda, USA). SAB results before rituximab therapy were positive for class I and class II antibodies and ranged from 3 to 91%. The result after therapy showed a decrease in the percentage of antibodies of both classes and ranged from 0 to 60%. The results of the reaction of FCXM with serum obtained before and after rituximab therapy do not differ significantly. All results of the FCXM reaction are the same before and after trepapium, except for one patient in whom the cross-match with B cells was weakly positive before therapy, and showed a negative result after therapy. This is associated with a decrease in MFI levels of donor-specific antibodies DRB11 from 4901 to 1466 after receiving rituximab. There is a big difference from the results of CDC-XM with FCXM delivered with B cells. FCXM for the second class showed a negative result in all cases, while in CDC-XM a positive result was seen in all cases with an intensity of +4 to +8. It is assumed that the presence of rituximab in the serum did not affect the result of FCXM and therefore this type of analysis may be optimal for use in patients who received rituximab therapy without waiting for the drug to be eliminated from the body. Conversely, the CDC-XM assay should not be used in patients receiving rituximab and should only be administered after a drug washout time has been observed. The results obtained are intermediate; due to the insufficient number of observations, these studies will continue. In addition, in the future, the use of anti-rituximab monoclonal antibodies (Anti-Rituximab Antibody) is envisaged to inhibit rituximab in the patient’s serum before cross-match testing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.075
Threshold uncertainty score0.313

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.266
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueTransplantationSame topicTraditional Chinese Medicine StudiesFrench-language works237,207